CA3214270A1 - Prodrugs of kv7 channel openers - Google Patents
Prodrugs of kv7 channel openers Download PDFInfo
- Publication number
- CA3214270A1 CA3214270A1 CA3214270A CA3214270A CA3214270A1 CA 3214270 A1 CA3214270 A1 CA 3214270A1 CA 3214270 A CA3214270 A CA 3214270A CA 3214270 A CA3214270 A CA 3214270A CA 3214270 A1 CA3214270 A1 CA 3214270A1
- Authority
- CA
- Canada
- Prior art keywords
- depression
- disorder
- compound
- disorders
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163163470P | 2021-03-19 | 2021-03-19 | |
| US63/163,470 | 2021-03-19 | ||
| PCT/US2022/021059 WO2022198116A1 (en) | 2021-03-19 | 2022-03-20 | Prodrugs of kv7 channel openers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3214270A1 true CA3214270A1 (en) | 2022-09-22 |
Family
ID=83321210
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3214270A Pending CA3214270A1 (en) | 2021-03-19 | 2022-03-20 | Prodrugs of kv7 channel openers |
| CA3214305A Pending CA3214305A1 (en) | 2021-03-19 | 2022-03-20 | Prodrugs of kv7 channel openers |
| CA3214084A Pending CA3214084A1 (en) | 2021-03-19 | 2022-03-20 | Prodrugs of kv7 channel openers |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3214305A Pending CA3214305A1 (en) | 2021-03-19 | 2022-03-20 | Prodrugs of kv7 channel openers |
| CA3214084A Pending CA3214084A1 (en) | 2021-03-19 | 2022-03-20 | Prodrugs of kv7 channel openers |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20240300894A1 (https=) |
| EP (3) | EP4308545A4 (https=) |
| JP (2) | JP2024511057A (https=) |
| KR (2) | KR20230159506A (https=) |
| CN (3) | CN117295711A (https=) |
| AU (3) | AU2022240779A1 (https=) |
| BR (2) | BR112023019074A2 (https=) |
| CA (3) | CA3214270A1 (https=) |
| IL (2) | IL306005A (https=) |
| MX (2) | MX2023010976A (https=) |
| WO (3) | WO2022198116A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117860727A (zh) * | 2022-09-26 | 2024-04-12 | 江苏海洋大学 | 一种用于预防或治疗疼痛的药物组合物 |
| CN118553447B (zh) * | 2024-07-30 | 2024-11-08 | 四川大学华西医院 | 动态惊恐障碍治疗方案推荐系统、治疗系统及存储介质 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4200259A1 (de) * | 1992-01-08 | 1993-07-15 | Asta Medica Ag | Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung |
| JP2004115450A (ja) * | 2002-09-27 | 2004-04-15 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| US20060004197A1 (en) * | 2004-07-02 | 2006-01-05 | Thomas Thrash | Sulfonamide-based compounds as protein tyrosine kinase inhibitors |
| TWI453013B (zh) * | 2006-02-07 | 2014-09-21 | Lundbeck & Co As H | N-(2,4-二甲基-6-嗎啉-4-基-吡啶-3-基〉3,3-二甲基-丁醯胺之用途以及包含該化合物之醫藥品 |
| AU2009270768A1 (en) * | 2008-07-18 | 2010-01-21 | Valeant Pharmaceuticals International | Modified release formulation and methods of use |
| GB0813403D0 (en) * | 2008-07-22 | 2008-08-27 | Lectus Therapeutics Ltd | Potassium ion channel modulators & uses thereof |
| CN103073455B (zh) * | 2011-10-25 | 2015-08-19 | 中国科学院上海药物研究所 | 一类新型的kcnq钾通道激动剂、其制备方法和用途 |
| WO2013179298A2 (en) * | 2012-04-23 | 2013-12-05 | Cadila Healthcare Limited | A process for preparation of phenyl carbamate derivative and polymorphic forms thereof |
| US10526280B2 (en) * | 2014-11-13 | 2020-01-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | (2-amino-4-(arylamino)phenyl carbamates |
| MX2018015251A (es) * | 2016-06-10 | 2019-04-25 | Scifluor Life Sciences Inc | Derivados de 2-amino-4-(amino sustituido)fenil carbamato fluorinado. |
| AU2019335070A1 (en) * | 2018-09-06 | 2021-05-13 | Ian Cooke | Method of treating a sleep breathing disorder |
-
2022
- 2022-03-20 MX MX2023010976A patent/MX2023010976A/es unknown
- 2022-03-20 CA CA3214270A patent/CA3214270A1/en active Pending
- 2022-03-20 WO PCT/US2022/021059 patent/WO2022198116A1/en not_active Ceased
- 2022-03-20 CA CA3214305A patent/CA3214305A1/en active Pending
- 2022-03-20 AU AU2022240779A patent/AU2022240779A1/en active Pending
- 2022-03-20 US US18/282,934 patent/US20240300894A1/en active Pending
- 2022-03-20 EP EP22772333.5A patent/EP4308545A4/en active Pending
- 2022-03-20 WO PCT/US2022/021058 patent/WO2022198115A1/en not_active Ceased
- 2022-03-20 BR BR112023019074A patent/BR112023019074A2/pt unknown
- 2022-03-20 AU AU2022239618A patent/AU2022239618A1/en active Pending
- 2022-03-20 KR KR1020237035629A patent/KR20230159506A/ko active Pending
- 2022-03-20 BR BR112023019077A patent/BR112023019077A2/pt unknown
- 2022-03-20 MX MX2023010978A patent/MX2023010978A/es unknown
- 2022-03-20 EP EP22772332.7A patent/EP4308544A4/en active Pending
- 2022-03-20 US US18/282,943 patent/US20240208896A1/en active Pending
- 2022-03-20 JP JP2023557407A patent/JP2024511057A/ja active Pending
- 2022-03-20 CN CN202280034079.2A patent/CN117295711A/zh active Pending
- 2022-03-20 IL IL306005A patent/IL306005A/en unknown
- 2022-03-20 IL IL306004A patent/IL306004A/en unknown
- 2022-03-20 CA CA3214084A patent/CA3214084A1/en active Pending
- 2022-03-20 AU AU2022237675A patent/AU2022237675A1/en active Pending
- 2022-03-20 KR KR1020237035814A patent/KR20230159531A/ko active Pending
- 2022-03-20 CN CN202280034761.1A patent/CN117355503A/zh active Pending
- 2022-03-20 WO PCT/US2022/021057 patent/WO2022198114A1/en not_active Ceased
- 2022-03-20 JP JP2023557288A patent/JP2024511997A/ja active Pending
- 2022-03-20 CN CN202280034756.0A patent/CN117321031A/zh active Pending
- 2022-03-20 EP EP22772331.9A patent/EP4308543A4/en active Pending
- 2022-03-20 US US18/282,940 patent/US20240228434A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117295711A (zh) | 2023-12-26 |
| IL306004A (en) | 2023-11-01 |
| US20240228434A1 (en) | 2024-07-11 |
| AU2022237675A1 (en) | 2023-10-12 |
| BR112023019077A2 (pt) | 2023-12-05 |
| IL306005A (en) | 2023-11-01 |
| US20240300894A1 (en) | 2024-09-12 |
| JP2024511997A (ja) | 2024-03-18 |
| BR112023019074A2 (pt) | 2023-12-05 |
| MX2023010978A (es) | 2023-12-07 |
| EP4308544A1 (en) | 2024-01-24 |
| WO2022198116A1 (en) | 2022-09-22 |
| KR20230159506A (ko) | 2023-11-21 |
| WO2022198116A9 (en) | 2022-10-27 |
| MX2023010976A (es) | 2023-12-07 |
| AU2022240779A1 (en) | 2023-10-12 |
| CA3214084A1 (en) | 2022-09-22 |
| CA3214305A1 (en) | 2022-09-22 |
| AU2022239618A1 (en) | 2023-10-05 |
| KR20230159531A (ko) | 2023-11-21 |
| CN117355503A (zh) | 2024-01-05 |
| JP2024511057A (ja) | 2024-03-12 |
| EP4308543A4 (en) | 2025-04-30 |
| EP4308544A4 (en) | 2025-04-30 |
| WO2022198115A1 (en) | 2022-09-22 |
| EP4308543A1 (en) | 2024-01-24 |
| EP4308545A1 (en) | 2024-01-24 |
| EP4308545A4 (en) | 2025-04-30 |
| CN117321031A (zh) | 2023-12-29 |
| WO2022198116A8 (en) | 2023-11-09 |
| WO2022198114A1 (en) | 2022-09-22 |
| US20240208896A1 (en) | 2024-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2344447B1 (en) | Gaba conjugates and methods of use thereof | |
| AU2004285893B2 (en) | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | |
| KR20210134351A (ko) | 통합 스트레스 반응 경로의 억제제 | |
| US20240228434A1 (en) | Prodrugs of kv7 channel openers | |
| JP2024517498A (ja) | 化合物 | |
| TW201625521A (zh) | 類胡蘿蔔素衍生物、其藥理學上可容許之鹽或者其藥理學上可容許之酯類或醯胺類 | |
| US8765953B2 (en) | Compounds and methods for the treatment of pain and other diseases | |
| CN111253412A (zh) | α-倒捻子素衍生物及其应用 | |
| CA3216280A1 (en) | Class iia histone deacetylase (hdac) degrader ligands and methods of use thereof | |
| KR101061764B1 (ko) | 신경보호효과를 가지는 피루베이트 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물 | |
| US9505743B2 (en) | Matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases | |
| WO2004065385A1 (ja) | 新規含窒素環状化合物 | |
| EP4547645A1 (en) | Selective histone deacetylase 3 (hdac3) degraders and methods of use thereof | |
| WO2020059841A1 (ja) | プリオン病治療薬 | |
| TW201309691A (zh) | 促代謝性麩胺酸受體調節劑 | |
| MXPA06004449A (en) | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: SMALL ENTITY DECLARATION REQUEST RECEIVED Effective date: 20240722 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241118 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250314 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL Year of fee payment: 3 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: SMALL ENTITY DECLARATION DETERMINED COMPLIANT Effective date: 20250319 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250319 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250320 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250320 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - SMALL Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260313 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260313 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260314 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260314 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260325 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260325 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260325 |